Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.500
0.00 (0.00%)
At close: Feb 26, 2026, 4:00 PM EST
1.548
+0.048 (3.22%)
After-hours: Feb 26, 2026, 6:30 PM EST
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $14.18M in the quarter ending September 30, 2025, with 710.40% growth. This brings the company's revenue in the last twelve months to $70.86M, up 1,255.21% year-over-year. In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth.
Revenue (ttm)
$70.86M
Revenue Growth
+1,255.21%
P/S Ratio
9.07
Revenue / Employee
$688,000
Employees
103
Market Cap
640.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | 322.07M | 258.86M | 409.54% |
| Dec 31, 2018 | 63.21M | -28.48M | -31.06% |
| Dec 31, 2017 | 91.69M | 12.43M | 15.69% |
| Dec 31, 2016 | 79.26M | -50.76M | -39.04% |
| Dec 31, 2015 | 130.01M | 107.16M | 468.89% |
| Dec 31, 2014 | 22.85M | 20.63M | 928.53% |
| Dec 31, 2013 | 2.22M | 1.13M | 104.04% |
| Dec 31, 2012 | 1.09M | -760.00K | -41.10% |
| Dec 31, 2011 | 1.85M | -3.06M | -62.33% |
| Dec 31, 2010 | 4.91M | -5.79M | -54.13% |
| Dec 31, 2009 | 10.70M | -21.62M | -66.89% |
| Dec 31, 2008 | 32.32M | -17.80M | -35.51% |
| Dec 31, 2007 | 50.12M | -22.68M | -31.15% |
| Dec 31, 2006 | 72.80M | -2.88M | -3.81% |
| Dec 31, 2005 | 75.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 282.08M |
| Fulcrum Therapeutics | 80.00M |
| MeiraGTx Holdings | 27.42M |
| Ocugen | 5.37M |
| YD Bio | 510.36K |
| Allogene Therapeutics | 22.00K |
LXRX News
- 11 hours ago - Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 20 days ago - Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 27 days ago - Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 4 weeks ago - Lexicon Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain - GlobeNewsWire
- 5 weeks ago - Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - PRNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha